Back to Topics

Business, Trade & Innovation

How do veterinary medicines reach the market, and what steps are involved in their supply chain?

In the UK, the journey of a veterinary medicine from conception to use is meticulously regulated to ensure safety, efficacy and quality. It begins with pharmaceutical research, where new active ingredients are identified and tested to establish their safety and effectiveness and to consider whether they will be useful for vets, animal owners, and animal health and welfare. All data and findings from this research are compiled into a comprehensive dossier that is submitted to an independent regulatory authority for assessment; in the UK this work is overseen by the Veterinary Medicines Directorate (VMD). The VMD rigorously evaluates the evidence, considering potential impact on animal health, public health (especially for animals, or animal products, entering the food chain), the safety of the person administering the medicine and the environment.

If approved, the medicine is granted a Marketing Authorisation, which allows its legal sale and use within the UK. Manufacturers then scale up production adhering strictly to Good Manufacturing Practice (GMP) standards. Once produced, medicines move through a regulated supply chain from manufacturers to authorised wholesalers, and then to veterinary practices and licensed retailers such as veterinary practices and pharmacies. Throughout this process, robust traceability and cold-chain logistics are maintained to ensure product quality and integrity until the medicine reaches the end user.

What role does regulation play in encouraging innovation within the veterinary medicine and animal health sector?

Regulation of veterinary medicines in the UK, overseen by the VMD, is designed not just to safeguard animal welfare but also to foster innovation in veterinary medicine. By providing clear regulatory guidance and support, the VMD encourages companies to develop new, and more effective animal treatments, including cutting-edge therapies like new vaccines and gene-based solutions, to try and provide options for unmet therapeutic needs. Innovation is vital for advancing animal health, leading to the creation of new licensed veterinary medicines that help prevent disease, treat conditions more effectively, and enhance the quality of life for a range of animals. International collaboration and ongoing monitoring ensure that these innovations continue to meet the highest safety and efficacy standards. By supporting innovation through regulation, the UK enables improved animal health, improved standards of care, and enhanced welfare for animals nationwide.

How does international trade impact the availability of veterinary medicines?

International trade is vital to the UK veterinary medicines sector as many finished products are imported from the EU and the rest of the world. Trade enables a broad range of medicines to be accessible, allowing UK vets and animal owners to benefit from the latest treatments. The UK government, through the development of international trade agreements and global regulatory collaborative initiatives, works to reduce barriers and facilitate seamless supply.

Customs checks, divergent regulatory standards and other logistical hurdles can disrupt these complex supply chains, potentially leading to shortages or delays. The UK’s regulatory authorities and industry groups are engaging in efforts to harmonise standards, negotiate mutual recognition agreements and strengthen supply chain resilience. These initiatives aim to ensure a consistent and reliable supply of veterinary medicines, while upholding safety and quality standards to benefit animal health and welfare.

What are some recent innovations in veterinary medicines that are shaping the future of animal health?

The UK is at the forefront of several innovations in animal health. Advanced vaccines, including mRNA-based and recombinant vaccines, are improving disease prevention for livestock and companion animals. Precision medicine is gaining ground, with genetic testing and biomarker-driven treatments enabling more tailored, effective therapies for pets. The UK’s sophisticated surveillance systems and research collaborations have also spurred the development of new medicines and non-antibiotic therapies, supporting the fight against antimicrobial resistance.

Digital transformation is reshaping veterinary practice too. Telemedicine platforms now allow vets to advise animal owners remotely, especially in remote areas. Wearable health monitors for pets and livestock provide real-time health data, aiding early diagnosis and intervention. UK research institutions and biotech firms are also exploring regenerative medicine, such as stem cell therapies, to treat chronic animal diseases and injuries. Collectively, these trends are driving improved animal health, supporting UK veterinary professionals and enhancing welfare standards across the country.